1. In Vivo

Indian Leaders Climb Into Generics And Biosimilars Top 10

Companies Lower Down In The Top 50 See Movement Amid Mixed Fortunes

 
• By Dave Wallace

In a year that has seen significant changes throughout the generics and biosimilars industry ranking, the top 10 has welcomed two Indian off-patent leaders. Meanwhile, companies lower down our ranking have enjoyed mixed fortunes, leading to a number of significant movements in this year’s Generics Bulletin Top 50.  

Generics Bulletin Top 50 2023
THE COMPLETE RUNDOWN OF GB's TOP 50 RANKING • Source: Shutterstock 4

Change is a constant theme for our annual Generics Bulletin Top 50 ranking of the world’s leading generics and biosimilars companies, and this year’s rundown of off-patent industry titans is no different.

The top 10 players in 2023’s roster are a different group to last year’s leadership table, with two firms that were present in 2022’s top 10

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from 2024

More from Outlook